THE USE OF LEVOFLOXACINE IN OTORHINOLARYNGOLOGY: FEATURES AND ADVANTAGES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the problem of the use of fluoroquinolones in otorhinolaryngology. It has been established that the number of prescriptions of levofloxacin continues to grow in the world. The reason for the increase in the use of levofloxacin includes its more favorable benefit/risk ratio compared to many other fluoroquinolones as evidenced by the results of not only clinical but also ongoing pharmacoepidemiological studies.

Full Text

Restricted Access

About the authors

G. D Tarasova

FSBI SCC of Otorhinolaryngology, FMBA of Russia; FSBEI FPE RMACPE of RMH

Email: gtarasova@yandex.ru
MD, Chief Researcher; Prof. at the Department of Polyclinic Pediatrics

References

  1. Torres A., Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert. Opin. Pharmacother. 2012;13(8):1203-12.
  2. Яковлев С.В. Место фторхинолонов в лечении бактериальных инфекций. РМЖ. 2003;8:434-49.
  3. Salvo F., Polimeni G., Cutroneo P.M., Leone R., Confortic A., Moretti U., Motola D., Tuccori M., Caputi A.P. Allergic reactions to oral drugs: a case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacol. Res. 2008;58:202-7.
  4. Stahlmann R., Lode H.M. Risks associated with the therapeutic use of fluoroquinolones. Expert. Opin. Drug. Saf. 2013;12(4):497-505.
  5. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis 1999;28(2):352-64.
  6. Liu H.H. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug. Saf. 2010; 33:353-69.
  7. Blanca-López N., Andreu I., Torres Jaén M.J. Hypersensitivity reactions to quinolones. Curr. Opin. Allergy. Clin. Immunol. 2011;11:285-91.
  8. Carbon C. Effets indésirables de la lévofloxacine: données des études cliniques et de la pharmacovigilance. Therapie. 2001;56:35-40.
  9. Owens R.C., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 2005;41(Suppl. 2):144-57.
  10. Stahlmann R., Lode H.M. Risks associated with the therapeutic use of fluoroquinolones. Expert. Opin. Drug. Saf. 2013;12(4):497-505.
  11. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: A report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart J. 2006;27(17): 2099-114.
  12. Arabyat R.M., Raisch D.W., McKoy J.M., Bennett C.L. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Expert. Opin. Drug. Saf. 2015;14(11): 1653-60.
  13. Yee C.L., Duffy C., Gerbino P.G., Stryker S., Noel G.J. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr. Infect. Dis. J. 2002;21(6):525-29.
  14. Gilbert P., Das J., Foley I. Biofilms susceptibility to antimicrobials. Adv. Dent. Res. 1997; 11:160-67.
  15. Brooun A., Liu S., Lewis K. A dose-responsestudy of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2000;44:640-46.
  16. Lewis K., Spoering A.L., Kaldalu N., et al. Persisters: specialized cells responsible for biofilm tolerance. Biofilms, infection and antimicrobial therapy. Ed. by Pace J.L., Rupp M., Finch R.G. Taylor & Francis Group. 2005. P. 241-57.
  17. Goto T., Nakame Y., Nishida M., Ohi Y. In vitro bactericidal activities of beta-laktamases, amikacin and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology. 1999;53(5):1058-62.
  18. Bjarnsholt T. Biofilm infections. Springer, 2011. 314 p.
  19. Trampuz A., Zimmerli W. Diagnosis and treatment of infections associated with fracturefixation devices. Injury. 2006;37:59-66.
  20. Costerton J.W., Montanaro L., Arciola C.R. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs. 2005; 11:1062-68.
  21. Catheter-Related Infections (Infectious Disease and Therapy). Ed. by Seifert H., Bernd J., Farr B.M. Marcel Dekker.,2005. 519 p.
  22. Мележик И.А., Яворская Н.В., Шепелевич В.В., Кокозей В.Н. Роль боипленок Pseudomonas aeruginosa в развитии эндогенных инфекций. Бюллетень Оренбургского научного центра УрО РАН (электронный журнал)., 2013;3.
  23. Бузолева Л.С., Пузь А.В., Синебрюхов С.Л., Гнеденков С.В., Ким А.В., Еськова А.И., Пономарева А.Л. Имптантат-ассоциированные инфекции, связные с проблемой биопленкообразования. Современные проблемы науки и образования. 2016;5. URL: https://science-education.ru/ru/article/ view?id=25430.
  24. Shehab N., Patel P.R., Srinivasan A., Budnitz D.S. Emergency department visits for antibiotic associated adverse events. Clin. Infect. Dis. 2008;47:735-43.
  25. Крюков А.И., Кунельская Н.Л., Гуров А.В., Туровский А.Б., Изотова Г.Н. Клиника, диагностика и лечение бактериального синусита. Метод. рекомендации №23. М., 2013. 27 с.
  26. IMS Health National Sales Perspective (NSP), Y2014. Source File: NSP_2015-896 FQ AC 2014.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies